Investor Factsheet

Bayer is a life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are helping find solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.

All this goes to make up our corporate purpose: „Bayer: Science for a Better Life”

Bayer AG 2016 2017 Change
Total dividend payment 2,233 2,315 +3.7
Dividend per share (€) 2.70 2.80 +3.7

Employees 2016 2017 Change
Number of employees3 (Dec. 31) 99,592 99,820 +0.2
Personnel expenses (including pension expenses) (€ million) 9,459 9,528 +0.7
Proportion of women in senior management (%) 31 32
Proportion of employees with health insurance (%) 98 98
Fluctuation (voluntary / total) (%) 4.8 / 13.2 4.8 / 10.4
Hours of vocational and ongoing training per employee 23.0 23.4 +1.7

2016 figures restated
1 For definitions of the indicators see Annual Report 2017, Chapter "Alternative Performance Measures Used by the Bayer Group."
2 Group total 2016 including Covestro
3 Employees calculated as full-time equivalents (FTEs)
4 Number of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours
5 Quotient of total energy consumption and manufactured sales volume; Bayer excluding Currenta
6 Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and cooling (according to the market-based method); portfolio-adjusted in accordance with the GHG Protocol
7 Bayer excluding Currenta


Current Event

November 13, 2018

Q3 2018 Interim Report

Add to my calendar


Current Investor News

Bayer Stock

The capital stock of Bayer AG, amounting to Euro 2,387,333,027.84, is divided into 932,551,964 no-par registered shares. The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.

Security Identification No.
Bayer Code
ReutersXetra ®BAYGn.DE
Frankfurter WertpapierbörseBAYGn.F
BloombergXetra ®BAYN GY
Frankfurter WertpapierbörseBAYN GF

Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.

Bayer stock is listed on all the German stock exchanges.

Information about the dividend for fiscal 2017

The Annual Stockholders’ Meeting on May 25, 2018 resolved to use of the distributable profit for the fiscal year 2017 of EUR 2,900,000,000.00 an amount of EUR 2,402,253,862.40 to pay a dividend of EUR 2.80 per no-par share on the 857,947,808 no-par shares entitled to the dividend. The dividend yield calculated on the share price at year end 2017 amounts to 2.7 percent.


Stock ownership by region

Our ownership structure shows the international distribution of our capital stock. The highest proportion of our outstanding shares, almost 31 percent, is held by investors in the United States and Canada, followed by Germany with approx. 22 percent. From a regional perspective, Bayer has a stable ownership structure that has altered only slightly in recent years.

Ownership Structure by Country

Source: Ipreo

Credit Rating

Taking the planned acquisition of Monsanto into account, the rating agencies have confirmed the following ratings: 

Rating agencyLong-term ratingShort-term ratingOutlook
S&P Global RatingsBBBA-2stable

Future Perspectives

(published on September 5, 2018 in the Interim Report Q2 2018)

Economic Outlook

Corporate Outlook
Following the closing of the Monsanto acquisition on June 7, 2018, and taking into account the business development described in this report and the potential risks and opportunities, we have revised our expectations for fiscal 2018.

Our outlook now includes the sales and earnings contributions from Monsanto since the date of acquisition. As the transaction closed later than we had anticipated, 2018 earnings will be lower than we had projected in our February forecast including Monsanto due to the seasonality of the agricultural business. Our outlook takes into account the financing costs for the acquisition of Monsanto shares as well as the higher number of shares of Bayer AG following the capital increases on a pro rata temporis basis. The businesses divested to BASF are excluded as of their respective divestment dates.

The forecasts are based on the exchange rates as of June 30, 2018, and adjusted for currency effects4 to enhance the comparability of operating performance.

4 Using the average monthly exchange rates from 2017 (see table Bayer Group Consolidated Statements of Cash Flows)

We now expect Bayer Group sales of more than €39 billion (previously: below €35 billion), with more than €5 billion attributable to the acquired business. The divestment of selected businesses to BASF will reduce anticipated sales by approximately €1 billion. This forecast now corresponds to a mid-single-digit percentage increase (previously: low- to mid-single-digit percentage increase) on a currency- and portfolio-adjusted basis.

We now expect EBITDA before special items to increase by a low- to mid-single-digit percentage (previously: decline by a low-single-digit percentage). On a currency-adjusted basis, this corresponds to an increase by a high-single-digit percentage (previously: increase by a mid-single-digit percentage).

We now expect core earnings per share to come in at between €5.70 and €5.90 (previously: at the prior-year level). On a currency-adjusted basis, this corresponds to a decrease by a high-single-digit percentage (previously: increase by a mid-single-digit percentage). Prior-year core earnings per share were restated to €6.64 to reflect the bonus component of the capital increase with subscription rights, and this is taken into account here.

Forecast for Key Financial Data of the Group for 2018

Closing rates on June 30, 2018Currency-adjusted
SalesMore than €39 billionIncrease by a mid-single-digit percentage1
Development of EBITDA before special itemsIncrease by a low- to mid-single-digit percentageIncrease by a high-single-digit percentage
Development of core earnings per share€5.70 – €5.90Decrease by a high-single-digit percentage

1 Adjusted for currency and portfolio effects

We aim to pay out a dividend for 2018 that is at least at the same level as in the prior year, which would represent an upward deviation from our existing dividend policy (30-40% of core earnings per share as a mathematical basis for calculating the dividend payout). Due to the late closing of the Monsanto acquisition, anticipated core earnings per share for the full year will only include a small contribution from the acquired business. However, we will be able to utilize substantial operating cash flows from the acquired business due to seasonal trends. Bayer is also able to benefit from earnings contributions in the form of expected proceeds from the divestments to BASF and income from the sale of Covestro shares that has already been recognized. Overall, net financial debt at the end of the year will therefore be significantly lower than originally anticipated. Taking into account the cash flows and in view of the successful performance the combined business is expected to deliver, we want to enable our shareholders to share in our company’s success by paying out an attractive dividend.

For Pharmaceuticals, we confirm our previous sales and earnings guidance.

For Consumer Health, we confirm our expectations for sales and currency-adjusted EBITDA before special items. As for EBITDA before special items, we now anticipate a decline by a mid-single-digit percentage (previously: decline by a low-single-digit percentage) as a result of currency effects.

For Crop Science, we now forecast sales of slightly more than €14 billion (previously: more than €9.5 billion). As previously outlined, this includes a positive sales effect of more than €5 billion from the acquired business as well as a negative effect of approximately €1 billion from the divestment of selected businesses to BASF. We continue to expect a mid-single-digit percentage increase on a currency- and portfolio-adjusted basis. As for EBITDA before special items, we anticipate an increase by a mid-twenties percentage (previously: mid- to high-single-digit percentage). On a currency-adjusted basis, we now anticipate an increase of around 30% (previously: mid-teens percentage increase).

For the Animal Health segment, the Reconciliation and Bayer AG, we confirm our sales and earnings guidance.

Forecast for Other Key Data of the Group for 2018

Updated forecastForecast as of Feb. 28, 2018
Special chargesSpecial gain1 of around €1.9 billionSpecial charges of around €0.4 billion
Research and development expensesAround €4.9 billionAround €4.1 billion

Capital expenditures

Around €2.8 billionAround €2.2 billion
    of which for intangible assetsAround €0.6 billionAround €0.6 billion
Depreciation and amortizationAround €3.0 billionAround €2.2 billion
    of which on intangible assetsAround €2.0 billionAround €1.2 billion
Financial resultAround minus €1.2 billionAround minus €1 billion
Effective tax rate21.0%20.0%
Net financial debtaround €37 billionNet liquidity position2

1 Mainly comprising income from disposals of certain Crop Science activities as required by antitrust authorities
2 Excluding capital and portfolio measures




Forward-Looking Statements

This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer Investor Relations

Building W11
D-51368 Leverkusen

Dr. Jürgen Beunink
Phone: +49-214-30-65742

Peter Dahlhoff
Phone: +49-214-30-33022

Oliver Luckenbach
Phone: +49-214-30-20836

Laura Meyer
Phone: +1 314-694-8148

Oliver Maier
Head of Investor Relations
Phone: +49-214-30-81013

Judith Nestmann
Phone: +49-214-30-66836

Constance Spitzer
Phone: +49-214-30-33021